Skip to main content
. 2019 Dec 10;83(3):310–318. doi: 10.1097/QAI.0000000000002275

FIGURE 2.

FIGURE 2.

Snapshot and TRDF analyses of the proportion of participants with HIV-1 RNA <50 copies/mL or without TRDF at week 96 by baseline viral load and CD4+ cell count in the pooled ITT-E population from GEMINI-1 and GEMINI-2. 2DR, 2-drug regimen (dolutegravir + lamivudine); 3DR, 3-drug regimen (dolutegravir + tenofovir disoproxil fumarate/emtricitabine). aTRDF was a preplanned analysis at week 96. Percentages estimated from the TRDF Kaplan–Meier analysis.